ArticleMolecular and cellular biology1998
The immunoglobulin heavy chain locus control region increases histone acetylation along linked c-myc genes.
Article in Molecular and cellular biology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Differential regulation of immunoglobulin class switch recombination by the tumor suppressor p53.Scientific reports · 2026Article
- Killer immunoglobulin-like receptor transcriptional regulation: a fascinating dance of multiple promoters.Journal of innate immunity · 2011Review
- The current state of chromatin immunoprecipitation.Molecular biotechnology · 2010Review
- Dissecting the regulatory switches of development: lessons from enhancer evolution in Drosophila.Development (Cambridge, England) · 2010Review
- Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma.The Journal of experimental medicine · 2008Article
- The epigenetics of mantle cell lymphoma.Current treatment options in oncology · 2007Review
- Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency.Annals of the rheumatic diseases · 2007Article
- The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.Oncogene · 2007Article
- An insulator blocks spreading of histone acetylation and interferes with RNA polymerase II transfer between an enhancer and gene.Nucleic acids research · 2004Article
- A human globin enhancer causes both discrete and widespread alterations in chromatin structure.Molecular and cellular biology · 2003Article
- A complex chromatin landscape revealed by patterns of nuclease sensitivity and histone modification within the mouse beta-globin locus.Molecular and cellular biology · 2003Article
- A major role for the TATA box in recruitment of chromatin modifying complexes to a globin gene promoter.Proceedings of the National Academy of Sciences of the United States of America · 2003Article
- The beta -globin locus control region (LCR) functions primarily by enhancing the transition from transcription initiation to elongation.Genes & development · 2003Article
- Locus control regions.Blood · 2002Review
- Burkitt's and Burkitt-like lymphoma.Current treatment options in oncology · 2002Review
- Regulation of alternative splicing by a transcriptional enhancer through RNA pol II elongation.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Allele-specific underacetylation of histone H4 downstream from promoters is associated with X-inactivation in human cells.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2002Article
- Transcriptional consequences of topoisomerase inhibition.Molecular and cellular biology · 2001Article
- The murine beta-globin locus control region regulates the rate of transcription but not the hyperacetylation of histones at the active genes.Proceedings of the National Academy of Sciences of the United States of America · 2001Article
- Translocations involving c-myc and c-myc function.Oncogene · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In chromosome translocations characteristic of Burkitt lymphomas (BL) and murine plasmacytomas, c-myc genes become juxtaposed to immunoglobulin heavy-chain (IgH) sequences, resulting in aberrant c-myc transcription. Translocated c-myc alleles that retain the first exon exhibit increased transcription from the normally minor c-myc promoter, P1, and increased transcriptional elongation through inherent pause sites proximal to the major c-myc promoter, P2. We recently demonstrated that a cassette derived from four DNase I-hypersensitive sites (HS1234) in the 3'Calpha region of the IgH locus functions as an enhancer-locus control region (LCR) and directs a similar pattern of deregulated expression of linked c-myc genes in BL and plasmacytoma cell lines. Here, we report that the HS1234 enhancer-LCR mediates a widespread increase in histone acetylation along linked c-myc genes in Raji BL cells. Significantly, the increase in acetylation was not restricted to nucleosomes within the promoter region but also was apparent upstream and downstream of the transcription start sites as well as along vector sequences. Histone hyperacetylation of control c-myc genes, which was induced by the deacetylase inhibitor trichostatin A, mimics the effect of the HS1234 enhancer on expression from the c-myc P2 promoter, but not that from the P1 promoter. These results suggest that the HS1234 enhancer stimulates transcription of c-myc by a combination of mechanisms. Whereas HS1234 activates expression from the P2 promoter through a mechanism that includes increased histone acetylation, a general increase in histone acetylation is not sufficient to explain the HS1234-mediated activation of transcription from P1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.